Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01847391 · ClinicalTrials.gov registry record · Phase 1
A Phase 1 Study to Assess the Safety,Tolerability, and Pharmacokinetics of GS-6615 in Healthy Subjects
A Phase 1 study of Ischemic Heart Disease, sponsored by Gilead Sciences.
- Completed
- Registry status
- Phase 1
- Development phase
- 36
- Enrollment target
- 1
- Study location
NCT01847391: Completed Phase 1 study of Ischemic Heart Disease, sponsored by Gilead Sciences.
NCT01847391 is a Phase 1 study of Ischemic Heart Disease that has completed, run by Gilead Sciences. The registered enrollment target is 36 participants, below the 264-participant average among 14 other Ischemic Heart Disease trials with a reported enrollment target (86% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01847391, a Phase 1 study of Ischemic Heart Disease, has completed, sponsored by Gilead Sciences.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 36 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a phase 1, single-blind, randomized, placebo-controlled, multiple ascending dose study aimed to assess the safety, tolerability, and pharmacokinetics of GS-6615 in healthy subjects.
Primary Outcome
The primary outcome measure is the safety and tolerability of GS-6615 including neurological findings, adverse events, clinical laboratory tests, vital signs and ECG data (PR, RR, QRS, QT, and QTc \[Fridericia\] interval).
Conditions Studied
Interventions
- DRUG Placebo
- DRUG GS-6615
Study Locations (1)
Wisconsin
- Investigational Site - Madison
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2013-05 |
| Est. Completion | 2013-11 |
| Phase | Phase 1 |
What the finished NCT01847391 record still lists
NCT01847391 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 36 participants, a relatively small participant target, below the 264-participant average among 14 other Ischemic Heart Disease trials with a reported enrollment target (86% lower).
The record links to 1 condition, with Ischemic Heart Disease appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT01847391 reports a single indexed study location in Wisconsin.
Frequently Asked Questions
What is clinical trial NCT01847391 about?
NCT01847391 is a clinical study titled "A Phase 1 Study to Assess the Safety,Tolerability, and Pharmacokinetics of GS-6615 in Healthy Subjects". This is a phase 1, single-blind, randomized, placebo-controlled, multiple ascending dose study aimed to assess the safety, tolerability, and pharmacokinetics of GS-6615 in healthy subjects.
What is the current status of trial NCT01847391?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 36 participants. The study started on 2013-05. Estimated completion is 2013-11.
What conditions does trial NCT01847391 study?
This clinical trial studies the following conditions: Ischemic Heart Disease.
What interventions are being tested in trial NCT01847391?
The interventions under investigation include: Placebo (DRUG), GS-6615 (DRUG).
Who is sponsoring clinical trial NCT01847391?
This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01847391 being conducted?
This trial has 1 study location across Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ischemic Heart Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01847391's enrollment target sits among peer trials
36 14th of 14 higher than 1 of 14 other Ischemic Heart Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Ischemic Heart Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
AI-Enabled Direct-from-ECG Ejection Fraction (EF) Severity Assessment Using COR ECG Wearable Monitor
RECRUITING
-
Routine Validation and Reproducibility Testing of Laboratory Assays and Research Techniques Used for Endocrine, Cardiometabolic, and Musculoskeletal Disorder Research (VALD)
RECRUITING
-
Pulsed Field Ablation for Post-Infarction Ventricular Tachycardia
RECRUITING · NA
-
Single or Repeated Intravenous Administration of umbiliCAl Cord Mesenchymal sTrOmal Cells in Ischemic Cardiomyopathy
RECRUITING · Phase 2
-
Use of GeriKit to Better Phenotype Older Adults With Ischemic Heart Disease
RECRUITING · NA
-
Development of CIRC Technologies
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00929006 · 36 participants · Early Phase 1
Acute Progesterone Suppression of Wake vs. Sleep Luteinizing Hormone Pulse Frequency in Pubertal Girls With and Without Hyperandrogenism
- NCT01891318 · 36 participants · Phase 1
Neoadjuvant Radiosurgery for Resectable Brain Metastases: Phase I/II Study
- NCT02291848 · 36 participants · Phase 1
Tumor-Associated Antigen-Specific Cytotoxic T-Lymphocytes for Multiple Myeloma
- NCT02366819 · 36 participants · Phase 4
Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia